WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 48'2501 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 42'9381 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 16'714  16'666  16'615  16'561  16'504  15'860  14'890  14'087 
Births 180  181  182  184  186  198  190  171 
Surviving infants 179  180  182  183  185  197  189  170 
Pop. less than 5 years 882  891  919  939  969  983  927  882 
Pop. less than 15 years 2'870  2'882  2'908  2'930  2'959  2'944  2'715  3'183 
Female 15-49 years 3'800  3'830  3'853  3'876  3'893  3'953  3'957  3'539 

Number of reported case

(Click for retrospective incidence data for Netherlands (the))
Diphtheria
Japanese encephalitis
Measles 10  51  15  15  109  1'019  16  178 
Mumps 398  610  562  73 
Pertussis 13'552  6'726  2'912  6'202  8'661  4'836  471  30 
Polio*
Rubella 12 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Netherlands (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          97  97  97  97  97  97  97  96 
HepB_BD          99  98  93  94 
HepB3         
Hib3          97  97  97  97  97  96 
JapEnc         
MCV          96  96  96  96  96  96  94  91 
MCV2          93  93  92  93  93 
PCV1         
PCV3          96  96  96  96 
Pol3          97  97  97  97  97  96 
Rota1         
Rota_last         
Rubella1          96  96  96  96  96 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Netherlands (the))
DTP1 99  99  99  99  99  99  98  98 
DTP3 97  97  97  97  97  97  97  96 
HepB3
Hib3 97  97  97  97  97  96 
MCV 96  96  96  96  96  96  94  91 
PCV3 96  96  96  96 
Pol3 97  97  97  97  97  97  97  96 
Rota_last

Number of districts in the country 408  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 93
From 80 to 89% 5
From 50 to 79% 2
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTIPV 9 years; Yes
DTaPHibHepIPV 2, 3, 4, 11 months; Yes Children born from August 1, 2011 and children born before that have t least one parent from a country with prevalence >2%, if mother is HBsAg-positive and only for birth cohort 2008 and following cohorts in case of Down syndrome
DTaPHibIPV 2, 3, 4, 11 months; Yes all newborns born before August 1, 2011 and not in one of the following groups: children with at least one parent from a country with prevalence >2%, children of HBsAg-positive mothers and for cohort 2008 and following children with downsyndrome
DTaPIPV 4 years; Yes
HPV 12 years, + 1 month, + 6month; Yes girls only
HepB <48 hrs after birth; Yes children of carrier mothers; junior dosage at 1st contact, +1, +6 months for immigrants from endemic countries
MMR 14 months; 9 years; Yes
MenC_conj 14 months; Yes
Pneumo_conj 2, 3, 4, 11 months; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR No  No  No  No  No    No 
What years does the MYP cover? number             NA 
Nº of districts with microplans that include activities to raise immunization coverage number      

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 408  415  12  12    12  12 
Nº districts with DTP3 coverage >=80% number 400  406           
% of districts with DTP3 coverage >=80% From 0 to 100% 98  98           
Nº districts with measles (MCV1) coverage >=95% number 331  329           
% of districts with MCV1 coverage >=95% From 0 to 100% 81  79           

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  No  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100    100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.